medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2011, Number 4

<< Back Next >>

Rev Invest Clin 2011; 63 (4)

Immunization with monovalent oral vaccine against rotavirus in Mexico. Evaluation of the data of two years of the system of temporarily Adverse Event Reports Associated to Vaccination (ETAV)

Reyna-Figueroa J, Vidal-Vázquez RP, López-Collada VLR

Language: Spanish
References: 27
Page: 391-398
PDF size: 93.56 Kb.


ABSTRACT

Background. The gastrointestinal manifestations are the adverse events mainly studied to the application of the vaccine against rotavirus. Material and methods. In order subsequent to consider the risk of associated events taken care of the vaccination against rotavirus in infants, we realized a retrospective study of 2 years, evaluating 7,691,757 distributed doses of oral vaccine, in 2008 and 2009. Results. The risk considered of an event associated after the application of the oral vaccine against rotavirus is of 2.9 events by 1,000,000 distributed doses. Conclusions. The taken care of associated events were little common subsequent to the vaccination against rotavirus.


REFERENCES

  1. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ. More on RotaShield and Intussusception: the role ofa age at the time of vaccination. J Infect Dis 2005; 92(Suppl. 1): S36-S43.

  2. Chang CC, Chang MH, Lin TY, Lee HC, Hsieh WS, Lee PIJ. Formos Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Med Assoc 2009; 108(4): 280-5.

  3. Ward LR, McNeal MM, Steele D. Why does the world need another rotavirus vaccine? Therapeutics and Clinical Risk Management. JID 2008; 4(1): 49-63.

  4. O’Ryan ML, Hermosilla G, Osorio G. Rotavirus vaccines for the developing world. Curr Opin Infect Dis 2009; 22(5): 483-9.

  5. Nakagomi T, Nakagomi O. A critical review on a globally-licensed, live, orally-administrable, monovalent human rotavirus vaccine: Rotarix. Expert Opin Biol Ther 2009; 9(8): 1073-86.

  6. Block SL, Vesikari T, Goveia M, Rivers S, Adeyi B, Dallas M, Bauder J, Boslego J, Heaton P. Efficacy, immunogenicity, and safety of a pentavalent human- bovine (WC3) Reassortant Rotavirus Vaccine at the end of Shelf Life. Pediatrics 2009, 119(1): 11-8.

  7. Ball R, Iskander J, Parashar UD. Postlicensure Monitoring of Intussusception After RotaTeq Vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 2008; 121(6): 1206-12.

  8. Reyna FJ, Vidal VP, Hernández HLC, Esparza AM, Gómez AM, Richardson LCV. Evaluación de la seguridad de la vacuna contra rotavirus en lactantes: revisión sistemática de la literatura científica. Vacunas 2010; 11(2): 54-60.

  9. Richardson V, Hernandez J, Quintanar M, Esparza M, Johnson B, Gomez C, et al. Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico. N Engl J Med 2010; 362: 299-305.

  10. Whittembury A, Ticona M. Eventos supuestamente atribuidos a vacunación o inmunización (ESAVI). Rev Peru Epidemiol 2009; 13(3): 1-12.

  11. Eventos Temporalmente Asociados a Vacunación. Manual de Procedimientos: SSA; 2002.

  12. Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomized, doubleblind, controlled study. Vaccine 2009; 27(43): 5936-41.

  13. Patel MM, Clark AD, Glass RI, Greenberg H, Tate J, Santosham M, et al. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception. Vaccine 2009; 27(22): 2916-22.

  14. Tan N, Leong Y, Boo K, Hock S, Wah B, ELTeo H, et al. An update of paediatric intussusception incidence in Singapore: 1997-2007, 11 years of intussusception surveillance. Ann Acad Med Singappore 2009; 38(8): 690-2.

  15. Phua K, Hock S, Wah B, Shanta C, Goh P, Han H, et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2,464 singaporean infants. JID 2005: 192(Suppl. 1): S6-S16.

  16. Salinas B, Perez SI, Linhares A, Ruiz PGM, Guerrero ML, Yarzabal JP, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414. Pediatr Infect Dis J 2005; 24(9): 807-16.

  17. Dennehy PH. A Short report on the highlights of world-wide development of RIX4414 a North American experience Comparative evaluation nof safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. Vaccine 2006; 24(18): 3780-1.

  18. Ruiz PG, Perez SI, Velazquez R, Abate H, Beuer T, Clemens C, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354(1): 11-22.

  19. Verisaki T, Matson D, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. 2 safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354(1): 23-33.

  20. Pérez SI, Salinas B, Tomat M, Linhares A, Guerrero ML, Ruiz PG, et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. J Infect Dis 2007; 196(4): 537-40.

  21. Dennehy P, Goveia M, Dallas M, Heaton P. The integrated phase III safety profile of the pentavalent human bovine (WC3) reassortant rotavirus vaccine. Int J Infect Dis 2007; 11(Suppl. 2): S36-S42.

  22. Phua K, Hock S, Seng F, Goh P, Leong Y, Kumar S, et al. Immunogenicity, reactogenicity and safety of a diptheria –tetanus- acellular pertussis –inactivated polio and haemophillus influenzae type b combination vaccine in a placebo-controlled roravirus vaccine study. Ann Acad Ned Singapore 2008; 37(7): 546-53.

  23. Geier D, King P, Skykes L, Geier M. RotaTeq vaccine adverse events and policy considerations. Med Sci Monit 2008; 14(3): 9-16.

  24. Ciarlet M, Sani-Grosso R, Yuan G, Lui G, Heaton P, Gottesdiener K, et al. Concomitant use of the oral pentavalent human bovine reassortant rotavirus vaccine and oral poliovirus vaccines. Pediat Infect Dis J 2008; 27(10): 874-80.

  25. Lindsey NP, Schroeder BA, Miller ER. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26(48): 6077-82.

  26. Abarca VK. Vigilancia de eventos adversos a vacunas. Rev Chil Infect 2007; 24(1): 53-6.

  27. Organización Panamericana de la Salud. Vacunación segura: módulos de capacitación. Módulo I. Autoridad Regulatoria Nacional. Washington, D.C.: OPS; 2007.




2020     |     www.medigraphic.com